Search research articles
Contact Us
Filters
Showing results (91-100 of 96) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 96 results.
Cancer
|
March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma
Lisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.
JAMA Oncology
|
December 19, 2024
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial
Laura A Dawson, Kathryn A Winter, Jennifer J Knox, et al.
Journal of Applied Clinical Medical Physics
|
August 3, 2022
Abdominopelvic MR to CT registration using a synthetic CT intermediate
Jin Uk Heo, Feifei Zhou, Robert Jones, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 13, 2022
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504
Maura L Gillison, Robert L Ferris, Jonathan Harris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2025
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
Mitchell Machtay, Pedro A Torres-Saavedra, Wade Thorstad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2026
Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Sri Vemulamanda, Aditi Kothari, Loris De Cecco, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 96) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 96 results.
Cancer
|
March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma
Lisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.
JAMA Oncology
|
December 19, 2024
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial
Laura A Dawson, Kathryn A Winter, Jennifer J Knox, et al.
Journal of Applied Clinical Medical Physics
|
August 3, 2022
Abdominopelvic MR to CT registration using a synthetic CT intermediate
Jin Uk Heo, Feifei Zhou, Robert Jones, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 13, 2022
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504
Maura L Gillison, Robert L Ferris, Jonathan Harris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2025
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
Mitchell Machtay, Pedro A Torres-Saavedra, Wade Thorstad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2026
Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Sri Vemulamanda, Aditi Kothari, Loris De Cecco, et al.
Page
of 10